Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Metformin has beneficial effects in Alzheimer's disease model

April 5, 2019

Acceleron discontinues development of systemic muscle agent ACE-2494

April 5, 2019

First subject dosed in phase I study of SM-07883

April 5, 2019

Shenzhen Biocan Technologies patents APP-targeting shRNAs

April 4, 2019

BioArctic receives grant for collaborative research to improve immunotherapy for CNS disorders

April 4, 2019

New phase Ib/IIa trial studies RTB-101 for Parkinson's disease

April 3, 2019

ProQR Therapeutics discloses new HTT-targeting antisense oligonucleotides

April 3, 2019

Alector initiates first-in-human study of AL-003 for Alzheimer's disease

April 3, 2019

Stoke Therapeutics divulges new antisense oligomers

April 3, 2019

New Alzheimer's disease model differentiates the role of C99 from beta-amyloid

April 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.